25 Jan 2024 • Does the duration of type 2 diabetes modify the effects of sodium–glucose cotransporter 2 inhibitor canagliflozin on cardiovascular (CV) and kidney outcomes?

As per a recent study, canagliflozin consistently demonstrates cardiorenal benefits across varying durations of diabetes, with no significant heterogeneity.

The study found notable reductions in major adverse CV events, CV death, heart failure hospitalization, and kidney failure requiring therapy. Furthermore, canagliflozin reduced albuminuria progression and increased albuminuria regression.

These findings suggest that earlier treatment with canagliflozin confers consistent cardiorenal benefits to individuals with type 2 diabetes.

Source: Diabetes Care | Read full story